🚀 VC round data is live in beta, check it out!
Zealand Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zealand Pharma and similar public comparables like Duality Biotherapeutics, Aspen Pharmacare, Brightgene Bio-medical, Santen Pharmaceutical and more.
Zealand Pharma Overview
About Zealand Pharma
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Founded
1997
HQ
Employees
501
Website
Sectors
Financials (LTM)
EV
$1B
Zealand Pharma Financials
Zealand Pharma reported last 12-month revenue of $1B and EBITDA of $820M.
In the same LTM period, Zealand Pharma generated $1B in gross profit, $820M in EBITDA, and $771M in net income.
Revenue (LTM)
Zealand Pharma P&L
In the most recent fiscal year, Zealand Pharma reported revenue of $1B and EBITDA of $1B.
Zealand Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | $820M | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 67% | XXX | 76% | XXX | XXX | XXX |
| EBIT Margin | 67% | XXX | 77% | XXX | XXX | XXX |
| Net Profit | $771M | XXX | $1B | XXX | XXX | XXX |
| Net Margin | 63% | XXX | 70% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zealand Pharma Stock Performance
Zealand Pharma has current market cap of $4B, and enterprise value of $1B.
Market Cap Evolution
Zealand Pharma's stock price is $49.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $4B | -4.3% | XXX | XXX | XXX | $14.45 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZealand Pharma Valuation Multiples
Zealand Pharma trades at 1.0x EV/Revenue multiple, and 1.5x EV/EBITDA.
EV / Revenue (LTM)
Zealand Pharma Financial Valuation Multiples
As of April 21, 2026, Zealand Pharma has market cap of $4B and EV of $1B.
Equity research analysts estimate Zealand Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zealand Pharma has a P/E ratio of 4.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 1.5x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBIT | 1.5x | XXX | 1.1x | XXX | XXX | XXX |
| EV/Gross Profit | 1.0x | XXX | 0.8x | XXX | XXX | XXX |
| P/E | 4.6x | XXX | 3.4x | XXX | XXX | XXX |
| EV/FCF | 1.6x | XXX | 1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zealand Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zealand Pharma Margins & Growth Rates
Zealand Pharma's revenue in the last 12 month declined by (44%).
Zealand Pharma's revenue per employee in the last FY averaged $2.9M, while opex per employee averaged $0.7M for the same period.
Zealand Pharma's rule of 40 is (26%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zealand Pharma's rule of X is (105%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Zealand Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (44%) | XXX | (53%) | XXX | XXX | XXX |
| EBITDA Margin | 67% | XXX | 76% | XXX | XXX | XXX |
| EBITDA Growth | (84%) | XXX | (84%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (26%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (105%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 24% | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zealand Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zealand Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Duality Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aspen Pharmacare | XXX | XXX | XXX | XXX | XXX | XXX |
| Brightgene Bio-medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Santen Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| TransThera Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zealand Pharma M&A Activity
Zealand Pharma acquired XXX companies to date.
Last acquisition by Zealand Pharma was on XXXXXXXX, XXXXX. Zealand Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zealand Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZealand Pharma Investment Activity
Zealand Pharma invested in XXX companies to date.
Zealand Pharma made its latest investment on XXXXXXXX, XXXXX. Zealand Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zealand Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zealand Pharma
| When was Zealand Pharma founded? | Zealand Pharma was founded in 1997. |
| Where is Zealand Pharma headquartered? | Zealand Pharma is headquartered in Denmark. |
| How many employees does Zealand Pharma have? | As of today, Zealand Pharma has over 501 employees. |
| Who is the CEO of Zealand Pharma? | Zealand Pharma's CEO is Adam Steensberg. |
| Is Zealand Pharma publicly listed? | Yes, Zealand Pharma is a public company listed on Nasdaq Copenhagen. |
| What is the stock symbol of Zealand Pharma? | Zealand Pharma trades under ZEAL ticker. |
| When did Zealand Pharma go public? | Zealand Pharma went public in 2010. |
| Who are competitors of Zealand Pharma? | Zealand Pharma main competitors are Duality Biotherapeutics, Aspen Pharmacare, Brightgene Bio-medical, Santen Pharmaceutical. |
| What is the current market cap of Zealand Pharma? | Zealand Pharma's current market cap is $4B. |
| What is the current revenue of Zealand Pharma? | Zealand Pharma's last 12 months revenue is $1B. |
| What is the current revenue growth of Zealand Pharma? | Zealand Pharma revenue growth (NTM/LTM) is (44%). |
| What is the current EV/Revenue multiple of Zealand Pharma? | Current revenue multiple of Zealand Pharma is 1.0x. |
| Is Zealand Pharma profitable? | Yes, Zealand Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zealand Pharma? | Zealand Pharma's last 12 months EBITDA is $820M. |
| What is Zealand Pharma's EBITDA margin? | Zealand Pharma's last 12 months EBITDA margin is 67%. |
| What is the current EV/EBITDA multiple of Zealand Pharma? | Current EBITDA multiple of Zealand Pharma is 1.5x. |
| What is the current FCF of Zealand Pharma? | Zealand Pharma's last 12 months FCF is $734M. |
| What is Zealand Pharma's FCF margin? | Zealand Pharma's last 12 months FCF margin is 60%. |
| What is the current EV/FCF multiple of Zealand Pharma? | Current FCF multiple of Zealand Pharma is 1.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.